PEDIATRICS Vol. 79 No. 6 June 1987, pp. 953-959
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Amir, N.
Right arrow Articles by Bach, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amir, N.
Right arrow Articles by Bach, G.

Mucolipidosis Type IV: Clinical Spectrum and Natural History

Naomi Amir MD1, Joel Zlotogora MD1, and Gideon Bach PhD1

1 From the Florence Miller Neuropediatric Diagnostic Unit, Bikur Holim Hospital, and Department of Human Genetics, Hadassah University Hospital, Jerusalem

The clinical spectrum and developmental features of mucolipidosis type IV, a recessive lysosomal storage disorder, are presented. The evaluation was based on information from the clinical charts and information obtained from the families of 20 patients between the ages of 2 to 17 years. The clinical manifestations of the disease, profound psychomotor retardation and visual impairment, appear during the first year of life. Definitive diagnosis is made by electron microscopy which reveals storage organelles typical of the mucolipidoses. This study details, for the first time, the heterogeneity of the ophthalmologic features, specifically as pertains to the age of onset, degree and clinical course of the corneal opacities, and the retinal involvement. Although the top developmental level was found to be 12 to 15 months in language and motor function, the course of the disease is protracted for some children, who show only a slight improvement, and others, little if any deterioration despite the early infantile onset of the disease. This presentation provides guidelines for the clinical diagnosis of mucolipidosis type IV.

Key Words: lysosomal storage disorder • mucolipidosis IV • corneal opacity

Submitted on June 30, 1986




This article has been cited by other articles:


Home page
 J Child NeurolHome page
S. Bonavita, A. Virta, N. Jeffries, E. Goldin, G. Tedeschi, and R. Schiffmann
Diffuse Neuroaxonal Involvement in Mucolipidosis IV as Assessed by Proton Magnetic Resonance Spectroscopic Imaging
J Child Neurol, July 1, 2003; 18(7): 443 - 449.
[Abstract] [PDF]

Home page
 NeurologyHome page
G. Altarescu, M. Sun, D. F. Moore, J. A. Smith, E. A. Wiggs, B. I. Solomon, N. J. Patronas, K. P. Frei, S. Gupta, C. R. Kaneski, et al.
The neurogenetics of mucolipidosis type IV
Neurology, August 13, 2002; 59(3): 306 - 313.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
B. M. Hersh, E. Hartwieg, and H. R. Horvitz
The Caenorhabditis elegans mucolipin-like gene cup-5 is essential for viability and regulates lysosomes in multiple cell types
PNAS, April 2, 2002; 99(7): 4355 - 4360.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
S. M. Pradhan, L.-O. Atchaneeyasakul, B. Appukuttan, R. N. Mixon, T. J. McFarland, A. M. Billingslea, D. J. Wilson, J. T. Stout, and R. G. Weleber
Electronegative Electroretinogram in Mucolipidosis IV
Arch Ophthalmol, January 1, 2002; 120(1): 45 - 50.
[Abstract] [Full Text] [PDF]

Home page
 Sci SignalHome page
P. Lane, G. Hao, and S. S. Gross
S-Nitrosylation Is Emerging as a Specific and Fundamental Posttranslational Protein Modification: Head-to-Head Comparison with O-Phosphorylation
Sci. Signal., June 12, 2001; 2001(86): re1 - re1.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. Goldin, A. Cooney, C. R. Kaneski, R. O. Brady, and R. Schiffmann
Mucolipidosis IV consists of one complementation group
PNAS, July 20, 1999; 96(15): 8562 - 8566.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
A. L. Rose, P. M. Farmer, N. Mitra, K. E. Wisniewski, and R. K. Pullarkat
Clinical, Pathologic, and Neurochemical Studies of an Unusual Case of Neuronal Storage Disease With Lamellar Cytoplasmic Inclusions: A New Genetic Disorder?
J Child Neurol, February 1, 1999; 14(2): 123 - 129.
[Abstract] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C.-S. Chen, G. Bach, and R. E. Pagano
Abnormal transport along the lysosomal pathway in Mucolipidosis, type IV disease
PNAS, May 26, 1998; 95(11): 6373 - 6378.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. Schiffmann, N. K. Dwyer, I. A. Lubensky, M. Tsokos, V. E. Sutliff, J. S. Latimer, K. P. Frei, R. O. Brady, N. W. Barton, E. J. Blanchette-Mackie, et al.
Constitutive achlorhydria in mucolipidosis type IV
PNAS, February 3, 1998; 95(3): 1207 - 1212.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
B. M. Hersh, E. Hartwieg, and H. R. Horvitz
The Caenorhabditis elegans mucolipin-like gene cup-5 is essential for viability and regulates lysosomes in multiple cell types
PNAS, April 2, 2002; 99(7): 4355 - 4360.
[Abstract] [Full Text] [PDF]